Risk Factors for Acute Graft-versus-host Disease After Human Leukocyte Antigen-identical Sibling Transplants for Adults with Leukemia

Overview

Journal J Clin Oncol

Specialty Oncology

Date 2008 Nov 5

PMID 18981462

Citations 80

Authors

Theresa Hahn

Philip L McCarthy Jr

Mei-Jie Zhang

Dan Wang

Mukta Arora

Haydar Frangoul

Robert Peter Gale

Gregory A Hale

John Horan

Luis Isola

Richard T Maziarz

Jon J van Rood

Vikas Gupta

Joerg Halter

Vijay Reddy

Pierre Tiberghien

Mark Litzow

Claudio Anasetti

Stephen Pavletic

Olle Ringden

Affiliations

Soon will be listed here.

Abstract

Purpose: Acute graft-versus-host disease (GVHD) causes substantial morbidity and mortality after human leukocyte antigen (HLA)-identical sibling transplants. No large registry studies of acute GVHD risk factors have been reported in two decades. Risk factors may have changed in this interval as transplant-related techniques have evolved.

Patients And Methods: Acute GVHD risk factors were analyzed in 1,960 adults after HLA-identical sibling myeloablative transplant for acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), or chronic myeloid leukemia (CML) reported by 226 centers worldwide to the Center for International Blood and Marrow Transplant Research from 1995 to 2002. Outcome was measured as time from transplant to onset of grade 2 to 4 acute GVHD, with death without acute GVHD as a competing risk.

Results: Cumulative incidence of grade 2 to 4 acute GVHD was 35% (95% CI, 33% to 37%). In multivariable analyses, factors significantly associated with grade 2 to 4 acute GVHD were cyclophosphamide + total-body irradiation versus busulfan + cyclophosphamide (relative risk [RR] = 1.4; P < .0001), blood cell versus bone marrow grafts in patients age 18 to 39 years (RR = 1.43; P = .0023), recipient age 40 and older versus age 18 to 39 years receiving bone marrow grafts (RR = 1.44; P = .0005), CML versus AML/ALL (RR = 1.35; P = .0003), white/Black versus Asian/Hispanic race (RR = 1.54; P = .0003), Karnofsky performance score less than 90 versus 90 to 100 (RR = 1.27; P = .014), and recipient/donor cytomegalovirus-seronegative versus either positive (RR = 1.20; P = .04). Stratification by disease showed the same significant predictors of grade 2 to 4 acute GVHD for CML; however, KPS and cytomegalovirus serostatus were not significant predictors for AML/ALL.

Conclusion: This analysis confirmed several previously reported risk factors for grade 2 to 4 acute GVHD. However, several new factors were identified whereas others are no longer significant. These new data may facilitate individualized risk estimates and raise several interesting biologic questions.

Citing Articles

A randomized controlled trial of conventional GVHD prophylaxis with or without teprenone for the prevention of severe acute GVHD.

Kitamura W, Fujii K, Tsuge M, Mitsuhashi T, Kobayashi H, Kamoi C Ann Hematol. 2025; .

PMID: 39994018 DOI: 10.1007/s00277-025-06269-2.

Using T-lymphocyte subsets at engraftment to predict the risk of acute graft-versus-host disease in patients with thalassemia major: development of a new predictive nomogram.

Xiao H, Yang G, Huang Q, Wei Z, Gan Z, Wu M Ther Adv Hematol. 2024; 15:20406207241294054.

PMID: 39664034 PMC: 11632902. DOI: 10.1177/20406207241294054.

Volumetric modulated arc therapy total body irradiation improves toxicity outcomes compared to 2D total body irradiation.

Hui C, Simiele E, Lozko Y, Romero I, Skinner L, Binkley M Front Oncol. 2024; 14:1459287.

PMID: 39351359 PMC: 11439880. DOI: 10.3389/fonc.2024.1459287.

[Chinese expert consensus on the diagnosis and treatment of acute graft-versus-host disease after hematopoietic stem cell transplantation (2024)].

Zhonghua Xue Ye Xue Za Zhi. 2024; 45(6):525-533.

PMID: 39134482 PMC: 11310805. DOI: 10.3760/cma.j.cn121090-20240608-00214.

Role of Endoscopic Techniques in the Diagnosis of Complications of Allogeneic Hematopoietic Stem Cell Transplantation: A Review of the Literature.

Bangolo A, Dey S, Nagesh V, Gumer K, Avetisyan L, Islam S J Clin Med. 2024; 13(15).

PMID: 39124609 PMC: 11313381. DOI: 10.3390/jcm13154343.

References

Michallet M, Corront B, Bosson J, Molina L, Peissel B, Maraninchi D . Role of splenectomy in incidence and severity of acute graft-versus-host disease: a multicenter study of 157 patients. Bone Marrow Transplant. 1991; 8(1):13-7. View

Michallet M, Perrin M, Belhabri A, Molina L, Nicolini F, Tigaud J . Impact of cyclosporine and methylprednisolone dose used for prophylaxis and therapy of graft-versus-host disease on survival and relapse after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1999; 23(2):145-50. DOI: 10.1038/sj.bmt.1701529. View

Hill G, Ferrara J . The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood. 2000; 95(9):2754-9. View

Eisner M, August C . Impact of donor and recipient characteristics on the development of acute and chronic graft-versus-host disease following pediatric bone marrow transplantation. Bone Marrow Transplant. 1995; 15(5):663-8. View

Sullivan K, Kopecky K, Jocom J, Fisher L, Buckner C, Meyers J . Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med. 1990; 323(11):705-12. DOI: 10.1056/NEJM199009133231103. View

Przepiorka D, Weisdorf D, MARTIN P, Klingemann H, Beatty P, Hows J . 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995; 15(6):825-8. View

Yee G, Self S, McGuire T, Carlin J, Sanders J, Deeg H . Serum cyclosporine concentration and risk of acute graft-versus-host disease after allogeneic marrow transplantation. N Engl J Med. 1988; 319(2):65-70. DOI: 10.1056/NEJM198807143190201. View

Oh H, Loberiza Jr F, Zhang M, Ringden O, Akiyama H, Asai T . Comparison of graft-versus-host-disease and survival after HLA-identical sibling bone marrow transplantation in ethnic populations. Blood. 2004; 105(4):1408-16. DOI: 10.1182/blood-2004-06-2385. View

Holler E, Kolb H, Moller A, Kempeni J, Liesenfeld S, Pechumer H . Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood. 1990; 75(4):1011-6. View

10.

Anasetti C, Beatty P, Storb R, Martin P, Mori M, Sanders J . Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma. Hum Immunol. 1990; 29(2):79-91. DOI: 10.1016/0198-8859(90)90071-v. View

11.

Devergie A, Blaise D, Attal M, Tigaud J, Jouet J, Vernant J . Allogeneic bone marrow transplantation for chronic myeloid leukemia in first chronic phase: a randomized trial of busulfan-cytoxan versus cytoxan-total body irradiation as preparative regimen: a report from the French Society of Bone Marrow Graft.... Blood. 1995; 85(8):2263-8. View

12.

Przepiorka D, Shapiro S, Schwinghammer T, Bloom E, Rosenfeld C, Shadduck R . Cyclosporine and methylprednisolone after allogeneic marrow transplantation: association between low cyclosporine concentration and risk of acute graft-versus-host disease. Bone Marrow Transplant. 1991; 7(6):461-5. View

13.

Clift R, Buckner C, Thomas E, Bensinger W, Bowden R, Bryant E . Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood. 1994; 84(6):2036-43. View

14.

Blaise D, Maraninchi D, Archimbaud E, Reiffers J, Devergie A, Jouet J . Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission: a randomized trial of a busulfan-Cytoxan versus Cytoxan-total body irradiation as preparative regimen: a report from the Group d'Etudes de la Greffe de Moelle.... Blood. 1992; 79(10):2578-82. View

15.

. Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. J Clin Oncol. 2005; 23(22):5074-87. PMC: 1475795. DOI: 10.1200/JCO.2005.09.020. View

16.

Wojnar J, Giebel S, Krawczyk-Kulis M, Markiewicz M, Kruzel T, Wylezol I . Acute graft-versus-host disease. The incidence and risk factors. Ann Transplant. 2006; 11(1):16-23. View

17.

Lee S, Kukreja M, Wang T, Giralt S, Szer J, Arora M . Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia. Blood. 2008; 112(8):3500-7. PMC: 2954751. DOI: 10.1182/blood-2008-02-141689. View

18.

Storb R, Prentice R, Buckner C, Clift R, Appelbaum F, Deeg J . Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. Beneficial effect of a protective environment. N Engl J Med. 1983; 308(6):302-7. DOI: 10.1056/NEJM198302103080602. View

19.

Weisdorf D, Hakke R, Blazar B, Miller W, McGlave P, Ramsay N . Risk factors for acute graft-versus-host disease in histocompatible donor bone marrow transplantation. Transplantation. 1991; 51(6):1197-203. DOI: 10.1097/00007890-199106000-00010. View

20.

Nash R, Pepe M, Storb R, Longton G, Pettinger M, Anasetti C . Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood. 1992; 80(7):1838-45. View